looks like its getting ready to pop, page-6

Hi All

This from theChairmans address last year.
The $800t would cover probably half a dozen systems, we get some idea of the value of the first order after the validation/asessment period.

"We are currently planning to produce several pre-production prototypes for a small clinical validation study to establish the usability of new features enabled by the second generation platform, and this is concurrent with final engineering and documentation of the system ahead of regulatory submissions."

We could easily be cash flow positive 2012/13 given that Gus should get some sort of licensing deal from the GI negotiations. Sounds like most of the development to bring the products to market is done so should go straight to the bottom line.

I`m on at 10.5 so I guess I`m calling it a buy